• 1. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 2. An amorphous lanthanum–iridium solid solution with an open structure for efficient water splitting?
  Wei Sun,Chenglong Ma,Xinlong Tian,Jianjun Liao,Ji Yang,Chengjun Ge,Weiwei Huang J. Mater. Chem. A, 2020,8, 12518-12525
• 3. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 4. An all-solid-state asymmetric device based on a polyaniline hydrogel for a high energy flexible supercapacitor?
  Hamid Heydari,Mohammad B. Gholivand New J. Chem., 2017,41, 237-244
• 5. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Naphthyridines

Introduction to 8-chloro-2-methyl-1,7-Naphthyridine (CAS No. 930302-88-8)

8-chloro-2-methyl-1,7-Naphthyridine, identified by the Chemical Abstracts Service Number (CAS No.) 930302-88-8, is a significant heterocyclic compound that has garnered considerable attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the naphthyridine class, a structural motif known for its broad spectrum of biological activities and potential therapeutic applications. The presence of both chloro and methyl substituents in its molecular framework enhances its reactivity and functional diversity, making it a valuable scaffold for drug discovery and development.

The molecular structure of 8-chloro-2-methyl-1,7-Naphthyridine consists of a fused bicyclic system comprising a pyridine ring and a pyrimidine ring. The chloro group at the 8-position and the methyl group at the 2-position contribute to its unique electronic properties and influence its interactions with biological targets. Such structural features are often exploited to modulate binding affinity and selectivity in drug design. The compound's solubility profile and stability under various conditions further enhance its utility in synthetic chemistry and preclinical studies.

In recent years, 8-chloro-2-methyl-1,7-Naphthyridine has been extensively studied for its pharmacological potential. Research has demonstrated its efficacy as an intermediate in the synthesis of novel therapeutic agents targeting various diseases. One of the most compelling areas of investigation has been its role in developing inhibitors for enzymes involved in cancer metabolism. Studies have shown that derivatives of this compound can selectively inhibit key enzymes such as isocitrate dehydrogenase (IDH) and succinate dehydrogenase (SDH), which are aberrantly expressed in certain types of tumors. These findings have opened up new avenues for developing next-generation anticancer therapies.

Furthermore, 8-chloro-2-methyl-1,7-Naphthyridine has shown promise in the treatment of infectious diseases. Its structural framework allows for the design of compounds with potent antimicrobial and antiviral properties. Researchers have reported the synthesis of analogs that exhibit significant activity against resistant bacterial strains and viral pathogens. The ability to fine-tune the substituents on the naphthyridine core enables the creation of molecules with enhanced pharmacokinetic profiles, including improved bioavailability and reduced toxicity.

The compound's versatility also extends to its application in central nervous system (CNS) disorders. Preliminary studies suggest that derivatives of 8-chloro-2-methyl-1,7-Naphthyridine may interact with neurotransmitter receptors, offering potential treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. The chloro and methyl groups play a crucial role in modulating receptor binding, allowing for precise targeting of pathological pathways without affecting normal physiological functions.

From a synthetic chemistry perspective, 8-chloro-2-methyl-1,7-Naphthyridine serves as an excellent building block for constructing more complex molecules. Its reactivity with various functional groups enables the introduction of additional pharmacophores, expanding its therapeutic applications. Advanced synthetic methodologies, including transition-metal-catalyzed cross-coupling reactions and palladium-mediated transformations, have been employed to generate novel derivatives with tailored properties.

The pharmaceutical industry has taken notice of these findings, leading to increased investment in research programs focused on 8-chloro-2-methyl-1,7-Naphthyridine derivatives. Collaborative efforts between academic institutions and biotechnology companies are yielding promising candidates for clinical trials. The compound's well-documented synthetic pathways and favorable safety profile make it an attractive candidate for further development into market-ready drugs.

As our understanding of disease mechanisms continues to evolve, so does the demand for innovative therapeutic agents. 8-chloro-2-methyl-1,7-Naphthyridine stands at the forefront of this innovation, offering a versatile scaffold that can be modified to address a wide range of medical needs. Its potential is further amplified by ongoing advancements in computational chemistry and high-throughput screening techniques, which accelerate the discovery process.

In conclusion,8-chloro-2-methyl-1,7-Naphthyridine (CAS No. 930302-88-8) is a multifaceted compound with significant implications for modern medicine. Its unique structural features and broad biological activity make it a cornerstone in pharmaceutical research. As scientists continue to explore its therapeutic potential, we can expect to see increasingly sophisticated derivatives entering clinical development pipelines in the near future.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)